v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Income Statement [Abstract]    
Revenue $ 0 $ 0
Operating expenses:    
Research and development costs 391,301 438,416
Intangible asset impairment 1,549,427 0
General and administrative 4,912,985 3,939,446
Total operating expenses 6,853,713 4,377,862
Loss from operations (6,853,713) (4,377,862)
Other income (expense):    
Interest income 733,351 1,415,561
Dividend income 380,682 0
Change in fair value of warrant liability (4,746,135) 10,446,000
Change in fair value of derivative liability 1,117,000 2,184,000
Change in fair value of convertible note receivable – Femasys 1,304,000 941,000
Change in fair value of warrant asset – Femasys (2,581,000) (2,091,000)
Change in fair value of investment – QCLS (7,732,000) 5,063,950
Change in fair value of warrant assets – QCLS (1,379,000) (2,367,684)
Gain on related party investment – QCLS 2,089,000 21,395,734
Gain on legal settlement – re-fair value of warrants 106,000 0
Issuance costs – Series C convertible preferred stock and warrants (1,234,553) 0
Unrealized gain (loss) on marketable securities (412,306) 66,316
Loss on legal settlement 0 (2,019,000)
Loss on issuance of Series C preferred stock (215,000) 0
Other expense, net (980) (965)
Total other income (expense), net (12,570,941) 35,033,912
Income tax benefit (expense) 0 0
Net income (loss) (19,424,654) 30,656,050
Preferred stock dividends (278,496) (1,129,759)
Undistributed income to Series B convertible preferred stock 0 (2,970,780)
Preferred stock accretion (3,503,222) (3,193,404)
Net income (loss) attributable to common stockholders $ (23,206,372) $ 23,362,107
Basic income (loss) per share attributable to common stockholders $ (2.77) $ 3.19
Diluted income (loss) per share attributable to common stockholders $ (2.77) $ 3.19
Weighted average shares outstanding basic 8,378,291 7,329,596
Weighted average shares outstanding diluted 8,378,291 7,329,596